PHOTOCURE ASA - NOTICE OF ANNUAL GENERAL MEETING
Published: 7 April 2010Medical congresses & eventsFinancial Investment & Stock
Please find enclosed an invitation to the annual general meeting at Photocure ASA on April 28th 2010, including attachments, attendance slip and proxy form.
Best regards,
Christian Fekete, CFO
Photocure ASA
Hoffsveien 48
0377 Oslo, Norway
Telephone: +47 22 06 22 10
Telefax: +47 22 06 22 18
www.photocure.com
About Photocure
Photocure is a Norwegian pharmaceutical company listed on the Oslo Stock Exchange (OSE: PHO). The company develops and sells pharmaceuticals and medical devices for the photodynamic treatment and diagnosis of cancer and selected dermatology indications.
Photocure's commercial activities includes own marketing and sales in selected markets as well as out-licensing on a regional or global basis prior to phase III.
Photocure has one proprietary pharmaceutical product on the market: Hexvix®, for the diagnosis of bladder cancer. Hexvix is approved in EU. In addition, the company has developed a proprietary light source, which is used in combination with the Visonac(TM) cream. Through worldwide studies, Photocure is continuously testing its products for new indications, and the aim is to develop a pipeline of follow-on products based on the Photocure Technology(TM) platform.
For more information about Photocure, visit our website at www.photocure.com.
Photocure®, the Photocure logo and Hexvix® are registered trademarks of Photocure ASA.
This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)